1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Rimbarlat

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2020

Location

Barcelona Spain

Primary Industry

Pharmaceuticals

About

Based in Barcelona, Spain and founded in 2020 by Luis Santiago (CEO), and Jorge Martin, Rimbarlat develops regenerative medicine for acute sports muscle injuries. In October 2022, Rimbarlat raised EUR 600,000 in venture funding from Capital Cell Investors. Rimbarlat is a biotechnology firm that focuses on producing medications that regenerate muscular tissue. The company is actively engaged in the study and development of regenerative therapies that enhance cell regeneration within muscle tissue. This breakthrough gives doctors a crucial tool for treating and mending serious muscle injuries, particularly in professional sports.
Current Investors
Capital Cell Investors

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Chiropractic, Orthopedic & Physical Therapy, Specialty Pharmaceuticals
Website
www.rimbarlat.org
Company Stage
Early Stage
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo